ReviewCurrent treatment options in oncology2023
Immunotherapy in HPV-Related Oropharyngeal Cancers.
Review in Current treatment options in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- A Current Perspective of Two of the Most Aggressive Head and Neck Cancers: Pharyngeal and Laryngeal.Current oncology (Toronto, Ont.) · 2025Pooled it
- 4-1BBCell reports. Medicine · 2025Trial
- Programmed cell death ligand 2 (PD-L2) expression is inversely correlated with human papillomavirus status in oropharyngeal squamous cell carcinoma (OPSCC) tumors.Oral oncology reports · 2026Article
- Article
- Therapeutic Landscape of HPV-Associated Cancers: From Mechanisms and Conventional Approaches to Future Innovations.Cancers · 2026Review
- Immunotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized clinical trials.Therapeutic advances in medical oncology · 2026Article
- Immunological dynamics in orthotopic compared with subcutaneous murine models of HPV-positive oropharyngeal cancer.Disease models & mechanisms · 2025Article
- Inciting commensal human papillomavirus immunity to combat cancer.Trends in cancer · 2025Article
- Vaccine-Based Immunotherapy for Oropharyngeal and Nasopharyngeal Cancers.Journal of clinical medicine · 2025Review
- Improved efficacy of therapeutic HPV DNA vaccine using intramuscular injection with electroporation compared to conventional needle and needle-free jet injector methods.Cell & bioscience · 2024Article
- Review
- Transcriptomic profiling of peripheral blood cells in HPV-associated carcinoma patients receiving combined valproic acid and avelumab.Molecular oncology · 2024Article
- Human Papillomavirus-Induced Chromosomal Instability and Aneuploidy in Squamous Cell Cancers.Viruses · 2024Review
- Molecular aspects of cervical cancer: a pathogenesis update.Frontiers in oncology · 2024Review
- The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival.Cell reports. Medicine · 2023Article
- Clinical, morphologic and molecular heterogeneity of HPV-associated oropharyngeal cancer.Oncogene · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementHuman papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) incidence has been increasing in recent decades. Treatment of the locally advanced HPV-related OPSCC includes a multidisciplinary approach. Immunotherapy with immune checkpoint inhibitors is used in the treatment of patients with recurrent/metastatic head and neck squamous cell carcinomas (HNSCC), including HPV-related OPSCC patients. There is increasing knowledge of the role of HPV in the tumor immune microenvironment. Therefore, HPV status of OPSCC plays an essential role in the design of immunotherapy clinical trials in both curative intent and metastatic settings. Moreover, HPV has become a potential therapeutic target, with vaccines and adoptive T-cell therapies being developed against HPV for the treatment of OPSCC. Several novel studies are designed to target HPV in combination with immune checkpoint inhibitors. Thus, HPV-related OPSCC remains a unique subgroup in the immunotherapy era.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.